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Purpose: The aim of this study was to prospectively assess whether
analysis of the tumor markers cytokeratin 19 fragments (CYFRA
21-1), carcinoembryonic antigen (CEA), and squamous cell carci-
noma (SCC) antigen in cytological fluid can improve the perfor-
mance of computed tomography (CT)-guided needle aspiration
biopsy (NAB) in the diagnosis of non-small cell lung cancer
(NSCLC).
Methods: A total of 100 patients (men:women 41:59, mean age: 63
years) with suspected malignant pulmonary lesions were prospectively
enrolled for CT-guided NAB procedures. Levels of CYFRA 21-1,
CEA, and SCC in the cytological fluid were measured by immunora-
diometric assays. The cutoff value for tumor markers was selected on
the basis of best accuracy through receiver operating characteristic
curves. The sensitivity and areas under the curve (AUC) of NAB
alone were compared with those of NAB combined with cytological
tumor markers (CYFRA 21-1, CEA, and SCC).
Results: Among 100 patients, 71 (71%) had NSCLC and 29 (29%)
had benign lesions. The sensitivity, specificity, and accuracy for
diagnosing NSCLC were 85.7%, 100%, and 89%, respectively, for
NAB alone. The sensitivity increased significantly for NAB com-
bined with a tumor marker compared with NAB alone (100% for
CYFRA 21-1, 92.9% for CEA, and 94.2% for SCC; p  0.001, p 
0.025, and p 0.014, respectively). The AUC of NAB with CYFRA
21-1 was significantly larger than the AUC of NAB alone (p 
0.001).
Conclusion: Evaluation of tumor markers CYFRA 21-1, CEA, and
SCC in the cytological fluid can improve the diagnostic performance
of CT-guided NAB for NSCLC. Of these markers, CYFRA 21-1 is
the most useful cytological tumor marker.
Key Words: CYFRA 21-1, CEA, SCC-Ag, Tumor marker, Cyto-
logical fluid, CT-guided needle aspiration biopsy (NAB).
(J Thorac Oncol. 2011;6: 1330–1335)
Lung cancer is one of the most prevalent and life-threaten-ing neoplasms in most parts of the world.1,2 Lung cancer
survival and individual therapeutic approaches largely de-
pend on the histology and stage of the disease at diagnosis,3
therefore early and accurate diagnosis of lung cancer is
important. In clinical practice, diagnostic tools commonly
used for lung cancer are computed tomography (CT) scans,
bronchoscopy, and sputum analysis, which all have limita-
tions in the early diagnosis of lung cancer. Therefore, biopsy
with histopathological examination is usually used to confirm
the diagnosis of lung cancer.2
CT-guided needle aspiration biopsy (NAB) of the lung
is a relatively safe and accurate method for diagnosing lung
lesions, even small lesions.4 The reported accuracy is rela-
tively high, ranging from 64 to 97%, and major complications
are rare4,5; however, transthoracic needle biopsy of lung
lesions has a false-negative rate of up to 20% in the diagnosis
of malignancy,3,6,7 and results revealing nonspecific benign
tissue or insufficient tissue for diagnosis are often not reliable
in excluding malignancy. Patients with these types of biopsy
results should have resampling of tissue with biopsy or
surgical resection, or close clinical and imaging follow-up.6
Tumor markers in the serum have been extensively
studied in lung cancer. Measurement of tumor marker con-
centrations is a much simpler and safer method than biopsy or
surgery for the diagnosis of lung cancer.7 Several tumor
markers including cytokeratin 19 fragments (CYFRA 21-1),
carcinoembryonic antigen (CEA), and squamous cell carci-
noma (SCC) antigen have been investigated for their diag-
nostic and prognostic value in non-small cell lung cancer
(NSCLC)7,8; however, there are no valuable tumor markers
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for lung cancer screening. Tumor markers in lung cancer are
useful tools in the follow-up of patients of cancer and are
used mainly for monitoring the efficacy of therapy and in the
early detection of recurrence.7,9 One of the main drawbacks
of serum tumor markers is the fact that high concentrations
are usually only found when the disease is at an advanced
stage.10,11 Therefore, it is very difficult to clinically detect a
lung tumor at an early stage with serum marker assays.10,12
Among the many possible types of samples for tumor marker
analysis, cytological fluid obtained from NAB has the poten-
tial to be an effective source, as it is obtained directly from
tumor tissue, thus many candidate biomarkers will be present
in high concentrations. The aim of this study was to prospec-
tively assess whether analysis of tumor markers CYFRA
21-1, CEA, and SCC in the cytological fluid can improve the
diagnostic performance of CT-guided NAB for NSCLC.
METHODS
Patient Selection
The study protocol was approved by the institutional
review boards, and written informed consent was obtained
from all patients.
From May 1, 2009, to October 31, 2009, 115 patients
who had a pulmonary nodule or mass suspicious for lung
malignancy on CT were prospectively enrolled in this
study. The inclusion criteria were age more than 20 years,
lesion size more than 8 mm, and solid lesions (ground
glass opacity component of 50%). The exclusion criteria
were a high index of suspicion for benign disease (e.g.,
tuberculosis) (n  6), histologically confirmed small cell
lung cancer or lymphoma (n  4), and refusal to provide
written informed consent (n  5).
The prebiopsy evaluation included reviews of CT
scans, laboratory studies, and medical records. All patients
underwent CT-guided NAB procedures, and all malignancies
had histologically and/or cytologically confirmed NSCLC.
The final study population comprised 59 men and 41 women,
aged 34 to 82 years (mean age, 63 years). Data collection was
systematized, and a standardized registration form was pre-
pared. For each patient, the following information was re-
corded: age, sex, history, biopsy site, size of nodule, NAB
results, pathology results, and laboratory data (cytological
fluid tumor markers CYFRA 21-1, CEA, and SCC).
CT-Guided NAB Technique
The biopsy procedures were performed by three expe-
rienced chest radiologists who had 3, 5, and 9 years of
experience performing thoracic biopsies. CT-guided biopsy
interventions were performed using a 16-MDCT scanner
(Somatom Sensation 16; Siemens Medical Solutions, Erlan-
gen, Germany) equipped with CARE Vision software (Sie-
mens Medical Solutions). The exposure parameters were 120
kV, 30 mAs, and a slice thickness of 6 mm. All procedures
were performed with the patients in a prone, supine, or lateral
decubitus position, depending on the location of the lesion.
The puncture area was cleaned with antiseptic solution fol-
lowed by administration of local anesthetic by subcutaneous
injection of 1% lidocaine (Xylocaine, AstraZeneca, Wilming-
ton, DE). In all cases, more than two aspiration specimens
were obtained to get enough specimen using 20- to 22-gauge
Chiba needles. Cytological fluid was also aspirated during the
procedure without additional needle punctures. Both aspira-
tion specimens and cytological fluid were obtained with one
needle puncture. A part of specimen was placed in 99% ethyl
alcohol for cytological examination, the rest of specimen and
fluid was prepared in tube for evaluation of cytological tumor
marker and immediately transferred for diagnosis.
Tumor Marker Analysis
Cytological fluid was collected from each patient be-
fore any therapy. Cytological fluid supernatants were ob-
tained by centrifugation at 2000g for 10 minutes and stored at
40°C before assaying for tumor markers using commercial
immunoassay kits. The technicians performing the assays
were blinded to the final diagnosis associated with the sam-
ples. CYFRA 21-1 levels were measured using an electro-
chemiluminescent immunoassay (CYFRA 21-1; Roche Diag-
nostics, Germany), CEA levels were measured using a
chemiluminescence immunoassay (Centaur CEA; Bayer
HealthCare, Tarrytown, NY), and SCC-Ag levels were mea-
sured using an immunoradiometric assay (SCC-RIABEAD;
SRL Inc., Japan). Tumor markers in each of the cytological
fluid samples were assayed twice, and the mean values were
used for analysis.
Statistical Analysis
Cytological results were evaluated and divided into the
following diagnostic categories: “malignant,” “suspicious for
malignancy,” “negative for malignancy,” and “nondiagnos-
tic” (e.g., cell paucity or samples with a few atypical cells). A
designation of “malignancy” or “suspicious for malignancy”
was considered a positive result. A designation of “negative
for malignancy” was considered a negative result. Nondiag-
nostic designations (n  9) were considered neither positive
nor negative, and the results were excluded from calculations
of sensitivity, specificity, and accuracy. A positive NAB
result was considered a true-positive result if there was
surgical confirmation and a false-positive result if no evi-
dence of malignancy was found during surgical resection (in
the absence of preoperative chemotherapy). Negative results
were considered true negative if regression was found on
subsequent CT or if no tumor was identified during exami-
nation of the surgical specimen. Surgical confirmation of
malignancy was considered a false-negative finding.
Receiver operating characteristics (ROC) curves were
constructed using the values of tumor markers in the cyto-
logical fluid, and a cutoff value was determined for differen-
tiation between malignant and benign lesions. The cutoff
level for each marker was selected based on the best diag-
nostic accuracy; if several cutoff points had the same accu-
racy, the value with the best specificity was chosen. Differ-
ences between the two groups (malignant and benign groups)
were evaluated using the 2 test or Fisher’s exact test. The
sensitivity, specificity, accuracy, positive predictive value
(PPV), and negative predictive value (NPV) of NAB alone
and NAB combined with cytological tumor markers (CYFRA
21-1, CEA, and SCC) were calculated. When analyzing the
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diagnostic yield of a combination of tumor markers, a case
was considered positive if at least one tumor marker was
positive and negative if all tumor markers were negative. We
also classified malignant cases according to tumor stage
based on the 7th Edition of lung cancer stage classification
suggested by the International Association for the Study of
Lung Cancer.13 The sensitivity, specificity, accuracy, PPV
and NPV of NAB alone and NAB combined with cytological
tumor markers (CYFRA 21-1, CEA, and SCC) were also
calculated according to tumor stage. To compare the perfor-
mance of NAB alone and NAB combined with tumor mark-
ers, ROC curves were constructed, and the area under the
curve (AUC) was compared. Comparisons were made using
the McNemar test for statistical significance of sensitivity,
accuracy, and AUC. Statistical analyses were performed with
SAS software (version 9.1.3 for Windows; SAS Institute,
Cary, NC), and p values less than 0.05 were considered
statistically significant.
RESULTS
Among 100 patients, 71 (71%) had NSCLC, and 29
(29%) had benign lesions. Table 1 summarizes patient char-
acteristics in the benign group, malignant group, and the total
population. There was no significant difference in any of the
characteristics, including age, sex, history of hypertension or
diabetes, tuberculosis status, and the size and location of
lesions between the two groups (p  0.05) (Table 1).
Of the 71 malignant lesions, 41 lesions were confirmed
by surgery such as pneumonectomy or lobectomy and 30
were confirmed by biopsy. Of the 29 benign lesions, six were
confirmed by video-assisted thoracic surgery or wedge resec-
tion, 10 were confirmed as benign clinically, and 13 were
eventually diagnosed as benign based on subsequent CT
scans that showed lesion regression. One case of malignancy
(adenocarcinoma [AC]) and eight cases of benign lesions
were nondiagnostic in cytological results. The histological
types of NSCLC, according to the WHO classification, were
as follows14: 54 patients with AC, 11 patients with SCC, one
patient with large cell carcinoma, and five patients with
NSCLC not otherwise specified.
The cytological fluid concentrations of CYFRA 21-1,
CEA, and SCC were 90.5  137 ng/ml (range, 1.67–500),
16.9  40.3 ng/ml (range, 0.1–233.79), and 21.3  45.2
ng/ml (range, 0.07–197.55) for malignant lesions and 10.9 
11.08 ng/ml (range, 1.24–47.7), 0.8  1.26 ng/ml (range,
0.1–5.84), and 4.5  14.5 ng/ml (range, 0.07–74.7) for
benign lesions, respectively. Levels of CYFRA 21-1, CEA,
and SCC in the cytological fluid were significantly higher in
the malignant group than in the benign group (p  0.05).
Using the ROC curves, the best cutoff values for the
tumor markers in the cytological fluid were 15.7 ng/ml for
CYFRA 21-1, 0.6 ng/ml for CEA, and 0.86 ng/ml for SCC
(Figure 1). Table 2 describes the sensitivity, specificity,
accuracy, PPV, and NPV of NAB alone and NAB combined
with cytological tumor markers in 91 patients. The sensi-
tivity, specificity, accuracy, PPV, and NPV of NAB alone
were 85.7%, 100%, 89%, 100%, and 67.7%, respectively.
The sensitivity increased significantly for NAB combined
with a tumor marker compared with NAB alone (100% for
CYFRA 21-1, 92.9% for CEA, and 94.2% for SCC: p 
0.001, p  0.025, and p  0.014, respectively) (Table 2).
The diagnostic accuracy improved significantly for NAB
combined with CYFRA 21-1 compared with NAB alone
(97.8% versus 89%, p  0.0209). Nevertheless, the accu-
racy of NAB combined with CEA or SCC and the accuracy
of NAB alone were not significantly different (p  0.738
and p  0.527, respectively).
When combinations of tumor markers were evaluated,
the sensitivity increased significantly for any combination of
tumor markers compared with NAB alone (p  0.001).
Nevertheless, accuracy was not significantly improved with
any combination of tumor markers compared with NAB
alone (p  0.05) (Table 2). The sensitivity of NAB with
CYFRA 21-1 was not significantly different from that of
NAB with any combination of tumor markers (p  0.05)
(Table 2).
Among the 71 malignant lesions, there were 38 cases of
stage 1, four cases of stage 2, 11 cases of stage 3, and 18 cases
of stage 4. In the results of subgroup analysis according to
tumor stage, the sensitivity, specificity, accuracy, PPV, and
NPV of NAB alone were 78.9%, 100%, 86.4%, 100%, and
72.4% for stage 1, 100%, 100%, 100%, 100%, and 100% for
stage 2, and 100%, 100%, 100%, 100%, and 100% for stage
3 and 88.8%, 100%, 94.8%, 100% and 91.4% for stage 4,
respectively. In stage 1, the sensitivity increased significantly
for NAB combined with a tumor marker compared with NAB
alone (100% for CYFRA 21-1, 89.5% for CEA, and 89.5%
for SCC: p 0.002, p 0.040, and p 0.040, respectively).
Nevertheless, the accuracy was no significantly different
between NAB alone and NAB combined with tumor markers
(96.6% for CYFRA 21-1, 86.4% for CEA, and 86.4% for
SCC: p  0.05). In stages 2, 3, and 4, the sensitivity and
accuracy were not significantly different between NAB alone
and NAB combined with a tumor markers (p  0.05). For
diagnosis of NSCLC, the AUC of NAB with CYFRA 21-1
was significantly larger than the AUC of NAB alone (0.993
versus 0.928, p  0.001). Nevertheless, the AUC of NAB
with CEA or SCC was not significantly larger than the AUC
TABLE 1. Patient Characteristics (N  100)
Characteristics
All
(n  100)
Malignant
(n  71)
Benign
(n  29) p
Mean age (SD) 63 (12) 64.7 (10) 60.1 (14) 0.1259
Male 59 44 (74.6%) 15 (25.4%) 0.3444
Hypertension 14 12 (85.7%) 2 (14.3%) 0.3399a
Diabetes mellitus 44 35 (79.5%) 9 (20.5%) 0.0951
Smoking 36 26 (72.2%) 10 (27.8%) 0.8399
Tuberculosis 13 7 (53.8%) 6 (46.2%) 0.1901a
Mean lesion size (mm) 26.88 27.59 25.18 0.4498
Location
Upper/middle lobe 55 37 18
Lower lobe 45 34 11 0.3638
a Fisher exact test.
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of NAB alone (0.950 versus 0.928, p  0.062 and 0.957
versus 0.928, p  0.057). The AUC of NAB with any
combination of tumor makers was significantly larger than
the AUC of NAB alone (p 0.05). Nevertheless, the AUC of
NAB with CYFRA 21-1 and the AUC of NAB with any
combination of tumor markers including CYFRA 21-1 were
not significantly different (p  0.05) (Table 3).
DISCUSSION
Our study demonstrates that additional evaluation of
cytological tumor markers (CYFRA 21-1, CEA, and SCC)
can improve sensitivity in the diagnosis of NSCLC in patients
undergoing CT-guided NAB. Among the three tumor mark-
ers, NAB combined with CYFRA 21-1 demonstrated the
highest sensitivity (100%) and accuracy (97.8%) for diagno-
sis of NSCLC.
The prognosis of NSCLC is poor; only 5% of patients
at clinical stage IIIb and almost none at clinical stage IV
survive for 5 years.8 Early detection of stage IA lung cancer
can increase the 5-year survival to 80%, compared with 15%
for overall NSCLC.2,3 Early detection of malignant small
nodules can lead to early treatment that can potentially be
curative.15 In clinical practice, CT-guided biopsy of lung
nodules is often performed to obtain a definitive diagnosis6
and is known to be a useful procedure for diagnosing pulmo-
nary nodules that are highly likely to be malignant, especially
in patients who are not candidates for surgery. Some authors
have reported that CT-guided biopsy has become an increas-
ingly accurate and sensitive technique for diagnosing pulmo-
nary masses and propose that it should be used for initial
diagnosis.16
FIGURE 1. Receiver operating characteristic (ROC) curves of the three cytologic tumor markers cytokeratin 19 fragments
(CYFRA 21-1) (A), carcinoembryonic antigen (CEA) (B), and squamous cell carcinoma (SCC) (C) for distinguishing benign le-
sions from malignant lesions. The best cutoff values for the tumor markers were 15.7 ng/ml for CYFRA 21-1, 0.6 ng/ml for
CEA, and 0.86 ng/ml for SCC.
TABLE 2. Comparison of the Diagnostic Results of NAB
Alone and NAB Combined with Cytological Fluid Tumor
Markers in 91 Patients
Diagnostic Method
Sensitivity
(%)
Specificity
(%)
Accuracy
(%)
PPV
(%)
NPV
(%)
NAB alone 85.7 100.0 89.0 100.0 67.7
NAB  tumor marker
CYFRA (15.7) 100.0 90.4 97.8 97.2 100.0
CEA (0.6) 92.9 81.0 90.1 94.2 77.2
SCC (0.86) 94.2 81.0 91.2 94.5 81.0
CYFRA  CEA 100.0 76.1 94.5 93.3 100.0
CYFRA  SCC 100.0 80.9 95.6 94.6 100.0
CEA  SCC 97.1 71.4 91.2 91.9 88.2
CYFRA  CEA 100.0 71.4 93.4 92.1 100.0
SCC
Numbers in parentheses are cutoff levels of tumor markers in ng/ml.
Nine cases of nondiagnostic results were excluded from calculations of sensitivity,
specificity, accuracy, PPV, and NPV.
PPV, positive predictive value; NPV, negative predictive value; CEA, carcinoem-
bryonic antigen; SCC, squamous cell carcinoma; CYFRA, cytokeratin 19 fragments;
NAB, needle aspiration biopsy.
TABLE 3. Comparison of the Diagnostic Performance of
NAB Alone and NAB with Cytological Fluid Tumor Markers
in 91 Patients
Tumor Marker AUC p
NAB alone 0.928 (95% CI: 0.887–0.969)
NAB with tumor marker
CYFRA (15.7) 0.993 (95% CI: 0.983–1.000) 0.001
CEA (0.6) 0.950 (95% CI: 0.913–0.988) 0.062
SCC (0.86) 0.957 (95% CI: 0.922–0.992) 0.057
CYFRA  CEA 0.993 (95% CI: 0.981–1.000) 0.001
CYFRA  SCC 0.995 (95% CI: 0.989–1.000) 0.001
CEA  SCC 0.966 (95% CI: 0.935–0.997) 0.023
CYFRA  CEA  SCC 0.995 (95% CI: 0.988–1.000) 0.001
Numbers in parentheses are cutoff levels of tumor markers in ng/ml.
Nine cases of nondiagnostic results were excluded from calculation of AUC.
AUC, areas under the curve; CI, confidence interval; CEA, carcinoembryonic
antigen; SCC, squamous cell carcinoma; CYFRA, cytokeratin 19 fragments; NAB,
needle aspiration biopsy.
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Although CT-guided biopsy is a relatively safe and
accurate method for diagnosing lung lesions, the results of
transthoracic needle biopsy of lung lesions are often falsely
negative in the diagnosis of malignancy,6 and nonspecific
results are common in NAB. The reported incidence of
nonspecific results ranges from 5.5 to 29%,5,16–19 and it has
been reported that 27% of the nonspecific results later turned
out to be malignant.20 Therefore, patients with suspected lung
malignancy but inconclusive results on initial lung biopsy
often require a second transthoracic lung biopsy or surgical
biopsy including video-assisted thoracic surgery.
We used cytological fluid instead of blood serum as a
new source of sample for tumor marker analysis. Although
blood is a good sample for serum biomarkers and contains a
large proteome that reflects a person’s health status,2,21–24 one
of the main drawbacks of serum tumor markers is that they
are typically only found in high concentrations near the tumor
tissue or when the disease is at an advanced stage.10,11
Therefore, it remains very difficult to clinically detect a lung
tumor at an early stage with serum marker assays.12,24 Cyto-
logical fluid might be a more effective sample than blood for
evaluation of tumor markers because it is obtained directly
from NAB and, therefore, might contain many candidate
biomarkers in high concentrations.24
According to the results of our study, additional eval-
uation of tumor markers in the cytological fluid can improve
the diagnostic performance of CT-guided NAB in patients
with NSCLC. Our results showed a significant increase in
overall sensitivity for NAB combined with a tumor marker
compared with NAB alone (100% for CYFRA 21-1, 92.9%
for CEA, and 94.2% for SCC; p  0.001, p  0.025 and p 
0.014, respectively). Furthermore, in subgroup analysis, the
sensitivity also increased significantly for NAB combined
with tumor marker results compared with NAB alone in stage
1 (100% for CYFRA 21-1, 89.5% for CEA, and 89.5% for
SCC: p 0.002, p 0.040, and p 0.040, respectively). By
calculating ROC curves, we observed that the AUC of NAB
with CYFRA 21-1 was significantly larger than the AUC of
NAB alone, which indicates that this cytological tumor
marker has additional value in the diagnosis of NSCLC. In
our study, the cytological marker CYFRA 21-1 had the best
diagnostic performance, similar to findings of previous stud-
ies.7,25 Wieskopf et al.26 reported that serum CYFRA 21-1
was a sensitive and specific tumor marker for diagnosing
NSCLC and seemed to be more sensitive and more specific
than other tumor markers, such as CEA and SCC. Another
study also showed that CYFRA 21-1 determination is useful
in identification of early NSCLC.11
In previous reports,8,27 the combination of several tu-
mor markers usually obtained better diagnostic performance
than any one marker alone. Ferrer et al.28 reported that the
combination of CYFRA 21-1, CEA, and CA 125 in either
serum or pleural fluid improves the diagnostic value of
pleural fluid cytology in the diagnosis of malignant pleural
effusion. In their study, the combination of CYFRA 21-1,
CEA, and CA 125 in pleural fluid achieved the best sensitiv-
ity (65%) with maximum specificity in the diagnosis of
malignant pleural effusion. We also analyzed whether a
combination of two or three tumor markers in the cytological
fluid can have additional value in the diagnosis of NSCLC
compared with a single tumor marker. The sensitivity and
AUC of NAB with CYFRA 21-1 was not significantly dif-
ferent from that of NAB with any combination of tumor
markers (p  0.05). This finding probably reflects the high
diagnostic value of CYFRA 21-1. Therefore, our results
suggest that adding other tumor markers to CYFRA 21-1 has
little additional value in terms of diagnostic performance for
NSCLC.
Our study has some limitations. The number of cases
involved was small, and the two major histological types
were not represented in equal numbers as more than half of
the cases included were ACs. Therefore, the value of cyto-
logical tumor markers shown in this study would be limited
in cell types other than AC. Furthermore, the biopsied sam-
ples were predominantly malignant because we excluded
cases that were most likely to be benign. Although NAB is a
safe and effective test, it is also an invasive procedure for
patients. Therefore, we deferred to follow-up imaging studies
in cases with highly suspected benign lesions than NAB
procedure.29–31
Second, the results may be influenced by the method
used for choosing the cutoff point for cytological tumor
markers. To the best of our knowledge, no other study on the
measurement of cytological tumor markers in patients with
NSCLC has been published; therefore, there are no reference
normal values for cytological fluid levels of various tumor
markers. In our study, we used ROC curves to determine the
cutoff values of tumor markers in the cytological fluid. The
ROC curve, best accuracy, best specificity, 95% specificity,
or using the same reference level as serum are all methods
that could be used to select the cutoff level. As diagnostic
tests require high specificity and sensitivity, we selected the
cutoff level for each marker based on the best diagnostic
accuracy. Nevertheless, because of the small sample size, we
did not perform independent validation of the cutoff values
selected for tumor markers as an independent series in this
study. Third, although most lesions had histopathologically
confirmed diagnoses, 30 malignant lesions were cytologically
confirmed, and 13 lesions required follow-up imaging studies
and clinical examinations.
In conclusion, measurement of the tumor markers
CYFRA 21-1, CEA, and SCC in the cytological fluid can
improve the diagnostic performance of CT-guided NAB for
NSCLC, and of these, CYFRA 21-1 is the most useful
cytological tumor marker. Analysis of tumor markers would
be a helpful ancillary studies for the diagnosis of lung cancer.
In cases where cytology tumor marker was positive, even if
biopsy turned out to be negative, underlying malignancy can
be suggested. Based on our study, cytological fluid seems to
be a suitable sample for assessing the presence and concen-
trations of tumor markers and might be clinically useful in the
diagnosis of lung cancer. This is particularly important as,
although lung biopsy using needle aspiration is a confirmative
method for diagnosis of lung cancer, NAB can give nondi-
agnostic results in up to 29% of cases. Performing the extra
step of measuring concentrations of tumor markers in the
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fluid that is aspirated does not require an additional puncture,
takes little extra time, and is easy. Therefore, we believe that
in cases of suspicious malignant nodules or masses showing
a negative or inconclusive cytological result, evaluation of
tumor markers in the cytological fluid may be a helpful
complementary tool for the diagnosis of lung cancer.
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